Raymond Kaempfer
Corporate Officer/Principal presso European Molecular Biology Organization
Posizioni attive di Raymond Kaempfer
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| European Molecular Biology Organization | Corporate Officer/Principal | - | - |
Storia della carriera di Raymond Kaempfer
Precedenti posizioni note di Raymond Kaempfer
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
Harvard University
 Harvard University Other Consumer ServicesConsumer Services Harvard University engages in the provision of teaching and research. It has twelve degree-granting Schools in addition to the Radcliffe Institute for Advanced Study, offering a global education. The university was founded in 1636 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | - | - |
| The Hebrew University of Jerusalem | Corporate Officer/Principal | - | - |
Atox Bio Ltd.
 Atox Bio Ltd. BiotechnologyHealth Technology Atox Bio, Inc. provides novel immune modulators for critically ill patients with severe infections. The firm discovers and develops novel immune modulators for critically ill patients with severe infections. Its main product is AB103, a novel immune modulator. The company was founded by Raymond Kaempfer and Gila Arad in 2003 and is headquartered in Ness Ziona, Israel. | Direttore/Membro del Consiglio | 01/01/2003 | - |
| Direttore Tecnico/Scientifico/R&S | 01/01/2003 | - | |
| Fondatore | 01/01/2003 | - |
Formazione di Raymond Kaempfer
| Massachusetts Institute of Technology | Doctorate Degree |
Statistiche
Distribuzione geografica
| Israele | 3 |
| Stati Uniti | 3 |
| Germania | 2 |
Posizioni
| Corporate Officer/Principal | 3 |
| Director/Board Member | 1 |
| Chief Tech/Sci/R&D Officer | 1 |
Settori
| Consumer Services | 3 |
| Health Technology | 2 |
| Finance | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Aziende private | 2 |
|---|---|
Atox Bio Ltd.
Atox Bio Ltd. BiotechnologyHealth Technology Atox Bio, Inc. provides novel immune modulators for critically ill patients with severe infections. The firm discovers and develops novel immune modulators for critically ill patients with severe infections. Its main product is AB103, a novel immune modulator. The company was founded by Raymond Kaempfer and Gila Arad in 2003 and is headquartered in Ness Ziona, Israel. | Health Technology |
| European Molecular Biology Organization |
- Borsa valori
- Insiders
- Raymond Kaempfer
- Esperienza
